Molbio Diagnostics IPO Review: PAT Jumped 96%, P/E at 54.63 & Full Analysis

Molbio Diagnostics Limited operates as an IP-driven medical technology enterprise, specializing in manufacturing high-entry-barrier point-of-care (POC) molecular diagnostics and devices.

Leveraging its "razor-and-blade" recurring revenue model, the Goa-based company holds a strong domestic footprint providing essential commercialised diagnostic test kits.

Transitioning to the public markets, the firm aims to raise up to ₹939.70 crores through a combination of a ₹200.16 crore fresh issue and a ₹739.70 crore Offer for Sale. Track all the Mainboard IPOs at a place IPO Calendar India 2026 | Upcoming & Live IPOs in India.

Scheduled to remain open for subscription from August 10 to August 12, 2026, the Molbio Diagnostics IPO has fixed a price band of ₹768 to ₹807 per equity share, requiring retail investors to bid for a minimum lot of 18 shares.

See our comprehensive analysis of the Molbio Diagnostics IPO, which includes the share price band, evaluation, final allocation dates, bidding status, and live grey market indicators.

Briefs of Molbio Diagnostics IPO Details

• Price Band: ₹768 – ₹807 per share (Employee Discount: ₹76 per share)
• IPO Open / Close Dates: 10 August 2026 / 12 August 2026
• Lot Size: 18 shares (Minimum retail investment: ₹14,526)
• Issue Size: 1,16,46,246 shares / Up to ₹939.70 crores
• Fresh Issue / OFS: Fresh Issue of 24,80,246 shares / OFS of 91,66,000 shares
• Registrar: KFin Technologies Limited
• Listing Exchange: BSE, NSE

IPO Reservation

• Face value: ₹1 per share
• Anchor offer: Up to 60% of the QIB Portion
• QIB-shares: Not more than 50% of the Net Offer
• NIIs-Shares offered: Not less than 15% of the Net Offer
• RIIs- Shares offered: Not less than 35% of the Net Offer

Where does the Molbio Diagnostics IPO GMP Currently Stand Today?

Track the latest GMP for this and other IPOs on our GMP Hub, where premiums are updated daily based on informal investor demand; however, GMP remains an unofficial market indicator and is neither regulated nor recognised by SEBI, BSE, or NSE.

Important GMP studies How Accurate is IPO Grey Market Premium in Predicting Listing Price?

What is the Official Subscription Timeline and Allotment Schedule for the Molbio Diagnostics IPO?

• IPO Open & Close Date: 10 August 2026 to 12 August 2026
• Basis of Allotment Date: 13 August 2026
• Refund Initiation Date: 14 August 2026
• Credit of Shares: 14 August 2026
• Listing Date: 17 August 2026

What are the Corporate Objectives Intended for the Capital Raised through the Molbio Diagnostics IPO?

The corporate leadership of Molbio Diagnostics plans to utilize the net capital raised from this fresh share issuance for the following primary purposes:

• R&D and Center of Excellence (CoE): An allocation of ₹105.53 crores is designated to establish a new Bengaluru research facility and CoE through its subsidiary, Bigtec Private Limited, fostering medical technology innovation.
• Manufacturing Automation: Approximately ₹72.28 crores will be utilised to upgrade machinery and automate processes at its existing Goa and Visakhapatnam manufacturing units.
• General Corporate Purposes: The final balance, capped at a maximum of 25% of gross new funding, is allocated for everyday business expenses and strategic projects, noting that the ₹739.70 crore Offer for Sale proceeds go entirely to selling shareholders.

Check this important analysis IPO Listing Performance Tracker 2026 – Complete Dataset of IPO Listing Gains in India

How is The Financial Performance of Molbio Diagnostics?

Review the condensed financial results detailed below, with figures quantified in Crores of Indian Rupees.

Source: RHP

Financial Observations

Total Income

The company registered a highly robust upward trajectory in its revenue streams over the observed fiscal periods.

• Total income expanded impressively from ₹840.66 crores in FY24 to ₹1,455.17 crores in FY26.
• This growth was fueled largely by the recurring "razor-and-blade" model, where test kit sales accounted for 71.58% of total revenue.
• Increased demand from Indian government agencies and international aid organizations formed the backbone of this top-line surge.

Profit After Tax

Net profitability experienced substantial sequential growth, recovering strongly from previous exceptional charges.

• PAT almost doubled from ₹83.54 crores in FY24 to ₹164.14 crores in FY26.
• The FY24 bottom line had been temporarily suppressed by ₹53.16 crores in exceptional write-downs for COVID-19 inventory obsolescence.
• Scaling operating leverage and consistent demand for diagnostic assays drove this sustained net earnings expansion.

EBITDA

Operating profits expanded remarkably, demonstrating the company's efficient management of variable production costs.

• EBITDA increased steadily from ₹185.09 crores in FY24 to ₹328.24 crores in FY26.
• However, the EBITDA margin compressed slightly from 24.97% to 22.56% due to rising royalty and commission expenses.
• Adjusting for heavy R&D expenditure, the EBITDA Pre-R&D margin stood at a highly competitive 28.57% in FY26.

Total Borrowing

The business utilised significant external debt to finance its strategic acquisitions and capacity expansions.

• Total borrowings surged from ₹123.16 crores in FY25 to ₹412.64 crores in FY26.
• This included a ₹224.96 crore floating-rate bank term loan to fund the acquisition of OptraScan INC.
• Despite this debt accumulation, the firm maintained a manageable Debt-to-Equity ratio of 0.32x.

Assets

The overall resource base of the company expanded exponentially to support its growing domestic and international footprint.

• Total assets grew dramatically from ₹1,221.06 crores in FY24 to ₹2,148.42 crores in FY26.
• This build-up is tied to a substantial cash position, growing inventory, and the recognition of ₹62.12 crores in Goodwill from acquisitions.
• High trade receivables (₹408.73 crores) linked to elongated government payment cycles also inflated this asset metric.

What is the P/E ratio and Peer Comparison of Molbio Diagnostics Limited?

The Price-to-Earnings (P/E) ratio, which measures a company's current market share price relative to its Earnings Per Share (EPS), is 54.63x for Molbio Diagnostics Limited, calculated using the upper price band of ₹807 and its FY26 EPS of ₹14.77.

Check this important analysis IPO Valuation vs Listing Performance Study 2026

Analysis:

Molbio Diagnostics Limited enters the primary market demanding an implied P/E multiple of approximately 54.63x at the upper price band.

When benchmarked against listed industry peers like Dr. Lal Pathlabs (62.20x) and Vijaya Diagnostics (81.02x), the issue appears to be priced competitively within the premium healthcare sector. 

However, traditional service-oriented diagnostic chains are not direct comparables; Molbio functions as an IP-driven medical device manufacturer, sitting closer in operational structure to Poly Medicure (P/E 52.61x).

With a robust Return on Net Worth (RoNW) of 14.55% and an expanding product portfolio, Molbio offers a distinct "razor-and-blade" recurring revenue profile compared to the capital-heavy service models of its listed peers.

What is The Industry Outlook of Molbio Diagnostics Limited?

Growth potential

• The Indian medical technology market is experiencing a massive tailwind driven by increasing healthcare budgets, government-led primary health centre upgrades, and a national focus on eradicating diseases like tuberculosis.
• The demand for robust point-of-care (POC) molecular diagnostics is rising as semi-urban and rural areas seek rapid, reliable testing capabilities without the necessity for advanced central laboratory infrastructure.
• Strategic acquisitions in digital pathology and AI-driven imaging offer significant long-term growth opportunities for device manufacturers expanding their holistic diagnostic ecosystems.

Market trends

• The healthcare diagnostic equipment sector operates under stringent regulatory compliance regimes, creating exceptionally high barriers to entry for unorganised or newer entities.
• A clear industry shift is occurring towards the "razor-and-blade" business model, wherein companies install diagnostic devices at competitive prices to secure highly profitable, recurring long-term revenue from consumable test kits.
• Dependency on public sector procurement remains a dominant feature; companies face continuous pressures regarding elongated working capital cycles and extended government trade receivables.

What Are The Strengths and Potential Risks of Molbio Diagnostics IPO?

Strengths:

• Recurring Revenue Model: Operating a "razor-and-blade" model ensures high predictability, with consumable test kits contributing a massive 71.58% of total revenue in FY26.
• Strong Returns: Despite heavy R&D investments and capital expansions, the firm generates a healthy Return on Net Worth (RoNW) of 14.55% and an EBITDA Pre-R&D margin of 28.57%.
• Market Positioning: As an IP-driven medical device manufacturer, the company holds high barriers to entry, distinguishing itself from traditional service-oriented pathology labs.

Risks:

• Customer Concentration: Over 84.56% of finished goods revenue is derived from Indian government agencies and international aid organisations, introducing severe public policy and budgetary risk.
• Working Capital Strain: Reliance on government contracts has elongated trade receivables to ₹408.73 crores, pushing working capital days to 166 and elevating credit loss provisions to ₹56.82 crores.
• Product Concentration: The business is heavily dependent on specific diagnostic assays, with tuberculosis tests alone accounting for 70.20% of finished goods sales in FY26.

Important IPO Resources

1. IPO Calendar India 2026 | Upcoming & Live IPOs in India

2. IPO Allotment Status – How to Check Allotment Status of IPO Shares

3. Latest IPO Subscription Status Today | Live Updates

4.IPO Glossary: 100+ Important Terms Every Investor Should Know

5. July 2026 IPO Review: 33 IPOs, ₹21140.52 Cr Raised & 56.37x Average Subscription

6. IPO Market Analytics

Key Considerations for Investors

• Customer Dependency: The firm is severely reliant on public sector health budgets, with government agencies and international aid accounting for 84.56% of finished goods revenue in FY26.
• Working Capital Strain: Heavy government exposure has elongated working capital days to 166, resulting in massive trade receivables of ₹408.73 crores and necessary expected credit loss provisions of ₹56.82 crores.
• Product Concentration: The business is primarily sustained by its tuberculosis assay, which generated 70.20% of the finished goods sales, leaving the company vulnerable to shifts in this specific disease vertical.
• Debt Expansion: Total borrowings surged to ₹412.64 crores in FY26 to finance strategic acquisitions, including a ₹224.96 crore floating-rate bank loan, slightly exposing margins to interest rate volatility.

Key Takeaways

• IPO Price Band: ₹768 to ₹807 per equity share (Employee discount of ₹76 per share)
• Lot Size: 18 shares (Minimum retail application of ₹14,526)
• Allotment Date: Allotment on 13 August 2026
• Listing Dates: Listing on BSE and NSE on 17 August 2026

FAQs on Molbio Diagnostics IPO

What is Molbio Diagnostics IPO GMP today?

Monitor current premium adjustments for this mainboard IPO on our central hub page, noting that unofficial indicators fluctuate daily according to changing market demand.

What is Molbio Diagnostics IPO price band?

The price band has been fixed at ₹768 to ₹807 per equity share, with a ₹76 discount for eligible employees.

What is Molbio Diagnostics IPO allotment date?

The final share allocation framework is officially set to be determined on 13 August 2026.

How to check Molbio Diagnostics IPO allotment status?

Upon finalisation, share allocation can be checked on the website of the official registrar, KFin Technologies Limited, using a PAN card number or application identification.

What is Molbio Diagnostics IPO listing date?

The official date set for the commencement of share market operations on BSE and NSE is 17 August 2026.

Investment Perspective on Molbio Diagnostics IPO

Molbio Diagnostics offers a highly scalable, technology-driven molecular moat with its WHO-endorsed Truenat platform, protected by thirteen years of rigorous research and development to obtain certification.

Its lucrative razor-and-blade business model shines, as recurring test kit sales commanded 73.98% of Fiscal 2026 finished goods revenue.

However, experienced stock pickers must balance this point-of-care expansion against key risks: a heavy 70.20% product concentration in tuberculosis diagnostic kits and an 84.56% customer dependency on government public health programs and international aid agencies.

Disclaimer: The information provided offers general financial analysis and lacks personal investment advice. It is essential to receive clearance from a SEBI-certified professional prior to undertaking any trading activities.